Transforming growth factor-beta in cancer and metastasis - PubMed (original) (raw)

Review

Transforming growth factor-beta in cancer and metastasis

Sonia B Jakowlew. Cancer Metastasis Rev. 2006 Sep.

Abstract

Transforming growth factor-beta (TGF-beta) is a multifunctional regulatory polypeptide that is the prototypical member of a large family of cytokines that controls many aspects of cellular function, including cellular proliferation, differentiation, migration, apoptosis, adhesion, angiogenesis, immune surveillance, and survival. The actions of TGF-beta are dependent on several factors including cell type, growth conditions, and the presence of other polypeptide growth factors. One of the biological effects of TGF-beta is the inhibition of proliferation of most normal epithelial cells using an autocrine mechanism of action, and this suggests a tumor suppressor role for TGF-beta. Loss of autocrine TGF-beta activity and/or responsiveness to exogenous TGF-beta appears to provide some epithelial cells with a growth advantage leading to malignant progression. This suggests a pro-oncogenic role for TGF-beta in addition to its tumor suppressor role. During the early phase of epithelial tumorigenesis, TGF-beta inhibits primary tumor development and growth by inducing cell cycle arrest and apoptosis. In late stages of tumor progression when tumor cells become resistant to growth inhibition by TGF-beta due to inactivation of the TGF-beta signaling pathway or aberrant regulation of the cell cycle, the role of TGF-beta becomes one of tumor promotion. Resistance to TGF-beta-mediated inhibition of proliferation is frequently observed in multiple human cancers, as are various alterations in the complex TGF-beta signaling and cell cycle pathways. TGF-beta can exert effects on tumor and stromal cells as well as alter the responsiveness of tumor cells to TGF-beta to stimulate invasion, angiogenesis, and metastasis, and to inhibit immune surveillance. Because of the dual role of TGF-beta as a tumor suppressor and pro-oncogenic factor, members of the TGF-beta signaling pathway are being considered as predictive biomarkers for progressive tumorigenesis, as well as molecular targets for prevention and treatment of cancer and metastasis.

PubMed Disclaimer

Cited by

Quercetin in Oncology: A Phytochemical with Immense Therapeutic Potential.
Kamal R, Paul P, Thakur S, Singh SK, Awasthi A. Kamal R, et al. Curr Drug Targets. 2024;25(11):740-751. doi: 10.2174/0113894501292466240627050638. Curr Drug Targets. 2024. PMID: 38988154 Review.
Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
Quach HT, Hou Z, Bellis RY, Saini JK, Amador-Molina A, Adusumilli PS, Xiong Y. Quach HT, et al. Expert Opin Investig Drugs. 2022 Nov;31(11):1187-1202. doi: 10.1080/13543784.2022.2152323. Epub 2022 Dec 5. Expert Opin Investig Drugs. 2022. PMID: 36448335 Free PMC article.
Desmoglein-2-integrin Beta-8 interaction regulates actin assembly in endothelial cells: deregulation in systemic sclerosis.
Giusti B, Margheri F, Rossi L, Lapini I, Magi A, Serratì S, Chillà A, Laurenzana A, Magnelli L, Calorini L, Bianchini F, Fibbi G, Abbate R, Del Rosso M. Giusti B, et al. PLoS One. 2013 Jul 11;8(7):e68117. doi: 10.1371/journal.pone.0068117. Print 2013. PLoS One. 2013. PMID: 23874518 Free PMC article.
YBX1/YB-1 induces partial EMT and tumourigenicity through secretion of angiogenic factors into the extracellular microenvironment.
Gopal SK, Greening DW, Mathias RA, Ji H, Rai A, Chen M, Zhu HJ, Simpson RJ. Gopal SK, et al. Oncotarget. 2015 May 30;6(15):13718-30. doi: 10.18632/oncotarget.3764. Oncotarget. 2015. PMID: 25980435 Free PMC article.
Prohibitin regulates TGF-beta induced apoptosis as a downstream effector of Smad-dependent and -independent signaling.
Zhu B, Zhai J, Zhu H, Kyprianou N. Zhu B, et al. Prostate. 2010 Jan 1;70(1):17-26. doi: 10.1002/pros.21033. Prostate. 2010. PMID: 19725029 Free PMC article.

Transforming growth factor-beta in cancer and metastasis - PubMed (original) (raw)